Human immunodeficiency virus (HIV) is the causative agent of AIDS (Acquired Immunodeficiency Syndrome), a disease which was first described in the United States in the early 1980s. Since its initial discovery, HIV/AIDS has risen to become a global pandemic, with over 30 million infected individuals worldwide.

In collaboration with members of the CHEETAH consortium and the NIGMS Specialized Centers for HIV/AIDS-Related Structural Biology, this project seeks to describe current understanding of the molecular mechanisms by which HIV gains entry to and exits from its target cells, an area of intense investigation by researchers around the globe.

Please note that the animation shown here is a work-in-progress, and will be further updated, refined and augmented over the coming years.  Additional animations will illustrate how antiretroviral drugs impact the life cycle, and how innate immunity can block HIV infection.

The HIV Life Cycle

How does HIV infection occur? This molecular animation depicts the process of how HIV infects a T cell and transforms the cell into a viral factory.

Click here to view a version of this animation without narration.

Download the HIV Life Cycle animation (narrated version, 523 MB)

Download the HIV Life Cycle animation (music-only version, 523 MB)

Credits:
Animated and narrated by Janet Iwasa (Department of Biochemistry, University of Utah)
Music written and performed by Joshua Roman
Music recorded by Jesse Lewis (Immersive Music Project)

Restriction Factors

Restriction factors act as one of our first lines of defense against viral invaders. These proteins, which are produced by the host cell, can work to inhibit the replication of broad classes of viruses, including HIV. Different restriction factors can target different points of the HIV cell cycle, including entry, reverse transcription, and budding. However, HIV has evolved mechanisms to counter these host defenses. By understanding these interactions, researchers may be able to develop new therapeutics against HIV. 

APOBEC3G and Viral Infectivity Factor (Vif)

APOBEC3G (A3G) is a protein that is produced by the host cell and is packaged into budding viruses. After these viruses infect a new host cell, A3G produces a large number of changes in the HIV genome, which causes the virus to become non-infectious due to catastrophic errors in its genetic sequence. This process is shown below, in the animation on the left.

As shown in the animation below (on the right), HIV counteracts A3G restriction by encoding a protein called viral infectivity factor (Vif). Vif hijacks the host’s molecular machinery and uses it to destroy A3G, preventing A3G from being packaged into new HIV virions.

  • Chen SH, Jang GM, Huttenhain R, et al. CRL4(AMBRA1) targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling. Embo j. Sep 14 2018;37(18)doi:10.15252/embj.201797508
  • Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol. Mar 20 2014;426(6):1220-45. doi:10.1016/j.jmb.2013.10.033
  • Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell. Sep 2008;134(6):995-1006. doi:10.1016/j.cell.2008.07.022
  • Kouno T, Luengas EM, Shigematsu M, et al. Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat Struct Mol Biol. Jun 2015;22(6):485-91. doi:10.1038/nsmb.3033
  • Li W, Ye Y. Polyubiquitin chains: functions, structures, and mechanisms. Cell Mol Life Sci. Aug 2008;65(15):2397-406. doi:10.1007/s00018-008-8090-6
  • Liu J, Nussinov R. Flexible cullins in cullin-RING E3 ligases allosterically regulate ubiquitination. J Biol Chem. Nov 2011;286(47):40934-42. doi:10.1074/jbc.M111.277236
  • Maiti A, Myint W, Kanai T, et al. Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA. Nat Commun. Jun 25 2018;9(1):2460. doi:10.1038/s41467-018-04872-8
  • Malim MH, Bieniasz PD. HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med. May 2012;2(5):a006940. doi:10.1101/cshperspect.a006940
  • Nakashima M, Ode H, Kawamura T, et al. Structural Insights into HIV-1 Vif-APOBEC3F Interaction. J Virol. Jan 15 2016;90(2):1034-47. doi:10.1128/jvi.02369-15
  • Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. Jan 2005;6(1):9-20. doi:10.1038/nrm1547
  • Wolfe LS, Stanley BJ, Liu C, Eliason WK, Xiong Y. Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J Virol. Jul 2010;84(14):7135-9. doi:10.1128/jvi.00031-10

TRIM5α

The tripartite-motif protein 5 alpha (TRIM5α) is a restriction factor that can potently block viral replication and is found in most primates. Acting as part of the innate immune system, TRIM5α (colored purple) can bind to the HIV capsid shell (yellow) that coats and protects the viral genome. Studies have shown that TRIM5α is a potent inhibitor of HIV-1 in old world monkeys, making them immune to HIV-1. Human TRIM5α, however, is not as effective as blocking HIV-1, but is thought to mediate restriction against other viruses.

Structural studies have shown that TRIM5 can form a cage-like structure surrounding the capsid. There are three proposed mechanisms by which TRIM5 can inhibit HIV infection as shown in this animation.

  • Ganser-Pornillos BK, Chandrasekaran V, Pornillos O, Sodroski JG, Sundquist WI, Yeager M. Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci U S A. Jan 11 2011;108(2):534-9. doi:10.1073/pnas.1013426108
  • Ganser-Pornillos BK, Pornillos O. Restriction of HIV-1 and other retroviruses by TRIM5. Nat Rev Microbiol. Sep 2019;17(9):546-556. doi:10.1038/s41579-019-0225-2
  • He C, Klionsky DJ. Atg9 trafficking in autophagy-related pathways. Autophagy. May-Jun 2007;3(3):271-4. doi:10.4161/auto.3912
  • Hodge CD, Spyracopoulos L, Glover JN. Ubc13: the Lys63 ubiquitin chain building machine. Oncotarget. Sep 27 2016;7(39):64471-64504. doi:10.18632/oncotarget.10948
  • Jimenez-Guardeño JM, Apolonia L, Betancor G, Malim MH. Immunoproteasome activation enables human TRIM5α restriction of HIV-1. Nat Microbiol. Jun 2019;4(6):933-940. doi:10.1038/s41564-019-0402-0
  • Li YL, Chandrasekaran V, Carter SD, et al. Primate TRIM5 proteins form hexagonal nets on HIV-1 capsids. Elife. Jun 2 2016;5doi:10.7554/eLife.16269
  • Martinez-Fonts K, Davis C, Tomita T, et al. The proteasome 19S cap and its ubiquitin receptors provide a versatile recognition platform for substrates. Nat Commun. Jan 24 2020;11(1):477. doi:10.1038/s41467-019-13906-8
  • Nascimbeni AC, Giordano F, Dupont N, et al. ER-plasma membrane contact sites contribute to autophagosome biogenesis by regulation of local PI3P synthesis. Embo j. Jul 14 2017;36(14):2018-2033. doi:10.15252/embj.201797006
  • Roganowicz MD, Komurlu S, Mukherjee S, et al. TRIM5α SPRY/coiled-coil interactions optimize avid retroviral capsid recognition. PLoS Pathog. Oct 2017;13(10):e1006686. doi:10.1371/journal.ppat.1006686
  • Sundquist WI, Pornillos O. Retrovirus Restriction by TRIM5α: RINGside at a Cage Fight. Cell Host Microbe. Dec 12 2018;24(6):751-753. doi:10.1016/j.chom.2018.11.013
  • Tooze SA, Yoshimori T. The origin of the autophagosomal membrane. Nat Cell Biol. Sep 2010;12(9):831-5. doi:10.1038/ncb0910-831
  • Wagner JM, Roganowicz MD, Skorupka K, et al. Mechanism of B-box 2 domain-mediated higher-order assembly of the retroviral restriction factor TRIM5α. Elife. Jun 2 2016;5doi:10.7554/eLife.16309
  • Wagner JM, Zadrozny KK, Chrustowicz J, et al. Crystal structure of an HIV assembly and maturation switch. Elife. Jul 14 2016;5doi:10.7554/eLife.17063
  • Yu A, Skorupka KA, Pak AJ, Ganser-Pornillos BK, Pornillos O, Voth GA. TRIM5α self-assembly and compartmentalization of the HIV-1 viral capsid. Nat Commun. Mar 11 2020; 11(1):1307 doi: 10.1038/s41467-020-15106-1.
  • Yudina Z, Roa A, Johnson R, et al. RING Dimerization Links Higher-Order Assembly of TRIM5α to Synthesis of K63-Linked Polyubiquitin. Cell Rep. Aug 4 2015;12(5):788-97. doi:10.1016/j.celrep.2015.06.072